T1	Participants 189 216	animals and healthy humans.
T2	Participants 318 382	Twenty-nine patients (6 type 1 and 23 type 2) with gastroparesis
T3	Participants 659 729	at baseline and after treatment with KC 11458 in a dose of 8 mg t.d.s.
T4	Participants 731 753	or placebo for 8 days.
